ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope
While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.
Immuno
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
NCCN visits Vietnam in continued cancer care collaboration
Bladder cancer diagnoses to top 300,000 in major markets by 2033
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
mRNA licensing agreements surge 800% amid GSK lawsuits
Oncolytics targets accelerated approval for oncolytic virus therapy
Neffy nasal spray: a game changer for asthma patients and epinephrine delivery?
